Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes

Efstathios Kastritis; Maria Gavriatopoulou; Eirini Solia; Foteini Theodorakakou; Vasiliki Spiliopoulou; Panagiotis Malandrakis; Ioannis Ntanasis‐Stathopoulos; Magdalini Migkou; Nikoleta Kokkali; Evangelos Eleutherakis‐Papaiakovou; Rodanthi Syrigou; Despina Fotiou; Evangelos Terpos; Meletios A Dimopoulos

doi:10.1016/j.clml.2023.07.013

Related publications

Article2022

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Efstathios Kastritis, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Ioannis Ntanasis‐Stathopoulos, Eirini Solia, Foteini Theodorakakou, Rodanthi Syrigou, Nikoletta‐Aikaterini Kokkali, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Μαρία Ρούσσου, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A Dimopoulos

Article2020

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Paul G. Richardson, Sundar Jagannath, Ajai Chari, Dan T. Vogl, Meletios A Dimopoulos, Philippe Moreau, David Dingli, Lee‐Jen Wei, Joshua Richter, Noa Biran, David S. Siegel, William M. Reichmann, Lingling Li, Shijie Tang, Jean‐Richard Saint‐Martin, Anita Joshi, Michael Kauffman, Jatin J. Shah, Sharon Shacham, Sagar Lonial

Article2023

Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes

Discussion(0)

Related publications

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma

Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study

CDK4/6 inhibitors and cardiovascular toxicity: Real-world evidence.

Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study